{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.0","upperLimit":"158.0","value":"85.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Defined as the time from first dose of ruxolitinib to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began oral administration of ruxolitinib at 5 mg BID; if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID. Participants did receive prednisone 2.5 mg/kg per day orally (PO) or methylprednisolone 2.0 mg/kg per day IV.","id":"OG000","title":"Ruxolitinib in Combination With Corticosteroids"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Participants","reportingStatus":"POSTED","timeFrame":"From Baseline until death, withdrawal of consent, or the end of the study, whichever occurs first (up to approximately 24 months)","title":"Failure-free Survival (FFS)","type":"SECONDARY","unitOfMeasure":"days"}